Clinical Trial Update: A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia [Phase 3]

View source ↗

Summary

Phase 3 trial assessing immunogenicity and safety of Infanrix-IPV/Hib given in a three-dose schedule with a booster in healthy infants in Russia; study complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Haemophilus Influenzae Type Infection
• Hepatitis B
• Pertussis
• Tetanus

Drugs mentioned

• Infanrix-IPV/Hib Vaccine (diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Diphtheria, Tetanus | Phase 3 | Status: COMPLETED | Results posted: 2019-07-19